DERIVADOS DE PIRROLIDINA COMO ANTAGONISTAS DEL RECEPTOR DE NK2.

    公开(公告)号:MX2010013311A

    公开(公告)日:2010-12-21

    申请号:MX2010013311

    申请日:2009-06-08

    Abstract: La presente invención se refiere a un compuesto de la fórmula I (ver fórmula (I)) en la que R1 es hidrógeno, halógeno, ciano o alquilo inferior; n es el número 1, 2 ó 3; R2 es hidrógeno o alquilo inferior; R3 es un anillo arilo o heteroarilo, los anillos están opcionalmente sustituidos por uno o dos sustituyentes R´; R´ se elige entre hidrógeno, halógeno, alquilo inferior, alcoxi inferior, alquilo inferior sustituido por halógeno, alcoxi inferior sustituido por halógeno, -S(O)2-alquilo inferior, CN, -NR4R5, -C(O)-alquilo inferior, heterociclilo o heteroarilo; R4/R5 con independencia entre sí son hidrógeno, -(CO)CF3 o alquilo inferior; o es un grupo heterocíclico no aromático (ver fórmula (II)) en el que X es N o CH; Y es -CH(R7)-; -N(R7´)-, u O o puede ser SO2; R6 es hidrógeno, alquilo inferior o hidroxi; R7 es hidrógeno, hidroxi, =O, alquilo inferior, alcoxi inferior, -S(O)2-alquilo inferior, -C(O)-alquilo inferior, -C(O)CH2O-alquilo inferior, -CH2CN, -C(O)CH2CN, -C(O)-cicloalquilo, el grupo cicloalquilo está opcionalmente sustituido por ciano, alquilo inferior, uno o dos átomos de halógeno, =O o por amino, o es -C(O)O-alquilo inferior, -NH- alquilo inferior, -NRC(O)O-alquilo inferior, -NRC(O)-alquilo inferior o -CH2O-alquilo inferior; y R7´ es hidrógeno, alquilo inferior, -(CH2)q-S(O)2-alquilo inferior, -(CH2)q-S(O)2-cicloalqui lo, -C(O)-alquilo inferior, -(CH2)q-cicloalquilo, -C(O)CH2-O-alquilo inferior, -(CH2)gCN, -C(O)CN, -C(O)CH2CN, alquilo inferior sustituido por halógeno, alquenilo inferior sustituido por halógeno, -C(O)- cicloalquilo, el grupo cicloalquilo está opcionalmente sustituido por ciano, alquilo inferior, uno o dos átomos de halógeno, =O o por amino, o es -C(O)O-alquilo inferior o -(CH2)qO-alquilo inferior y q es un número 0 - 3; o R6 y R7 junto con los átomos de carbono a los que están unidos pueden formar un anillo no aromático de cinco o seis miembros o R6 y R7´ junto con el nitrógeno y los átomos de carbono a los que están unidos pueden formar un anillo no aromático de cinco o seis miembros; p es el número 0, 1 ó 2; Ar es arilo o heteroarilo, los anillos están opcionalmente sustituidos por uno o dos sustituyentes R´´; R´´ se elige entre hidrógeno, halógeno, alquilo inferior, alquilo inferior sustituido por halógeno, alcoxi inferior, alcoxi inferior sustituido por halógeno, -O-CH2- cicloalquilo, -NR4R5, -CN, -CH(CH3)CN, -CH2O-alquilo inferior o pirrolilo; m es el número 0, 1 ó 2 y o es el número 0; o es el número 0, 1 ó 2 y m es el número 1, o sus sales farmacéuticamente activas, mezclas racémicas, enantiómeros, isómeros ópticos o formas tautómeras. Estos compuestos pueden utilizarse para el tratamiento de la depresión, la ansiedad o la esquizofrenia.

    4-hydroxy-4-methyl-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide

    公开(公告)号:AU2005247567B2

    公开(公告)日:2010-09-02

    申请号:AU2005247567

    申请日:2005-05-17

    Abstract: The present invention relates to the compound of formula which is 4-hydroxy-4-methyl-piperidine-1-carboxylic acid(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide, and to pharmaceutically acceptable acid addition salts thereof. It has been found that the compound is useful for the treatment or prevention of Alzheimer's disease, Parkinson's disease, Huntington's disease, neuroprotection, schizophrenia, anxiety, pain, respiration deficits, depression, ADHD (attention deficit hyper-activity disorder), drug addiction to amphetamines, cocaine, opioids, ethanol, nicotine, or cannabinoids, or for the treatment of asthma, allergic responses, hypoxia, ischemia, seizure, substance abuse, or for use as muscle relaxants, antipsychotics, antiepileptics, anticonvulsants and cardioprotective agents.

    DERIVADOS DE BENZOTIAZOL.
    35.
    发明专利

    公开(公告)号:ES2339867T3

    公开(公告)日:2010-05-26

    申请号:ES05771937

    申请日:2005-07-13

    Abstract: Compuestos de la fórmula general **(Ver fórmula)** en donde, R1, R2, de una forma independiente la una con respecto a la otra, son alquilo C1-C4 ó -(CH2)m-O-alquilo inferior, o forman, conjuntamente con el átomo de N al cual se encuentran éstas unidas, un anillo heterocíclico; R3, es hidrógeno ó alquilo C1-C4; R4, es alquilo C1-C4; Hetarilo, es 3-H-imidazol-2,4-diílo ó 1H-pirazol-1,4-diílo n, es 1 ó 2 y m, es 1 ó 2; y sales de adición de ácidos de éstos, farmacéuticamente aceptables.

    PYRROLIDINE DERIVATIVES AS NK2 RECEPTOR ANTAGONISTS

    公开(公告)号:CA2728054A1

    公开(公告)日:2009-12-23

    申请号:CA2728054

    申请日:2009-06-08

    Abstract: The present invention relates to a compound of Formula (I) wherein R1 is hydrogen, halogen, cyano or lower alkyl; n is 1, 2 or 3; R2 is hydrogen or lower alkyl; R3 is an aryl- or a heteroaryl ring, wherein the rings are optionally substituted by one or two substituents R'; R' is selected from hydrogen, halogen, lower alkyl, lower alkoxy, lower alkyl substituted by halogen, lower alkoxy substituted by halogen,-S(O)2-lower alkyl, CN, -NR4R5, -C(O)-lower alkyl, heterocyclyl or heteroaryl; R4/R5 are independently from each other hydrogen, -(CO)CF3 or lower alkyl or is a non aromatic heterocyclic group (II) wherein X is N or CH; Y is -CH(R7)-; -N(R7')-, or O or can be SO2; R6 is hydrogen, lower alkyl or hydroxy; R7 is hydrogen, hydroxy, =0, lower alkyl, lower alkoxy, -S(O)2-lower alkyl, -C(O)-lower alkyl, -C(O)CH2O-lower alkyl, -CH2CN, -C(O)CH2CN, -C(O)-cycloalkyl wherein the cycloalkyl group is optionally substituted by cyano, lower alkyl, one or two halogen atoms, =0 or by amino, or is -C(O)O-lower alkyl, -NH-lower alkyl, -NRC(O)O-lower alkyl, -NRC(O)-lower alkyl or -CH2O-lower alkyl; and R7' is hydrogen, lower alkyl, -(CH2)q-S(O)2-lower alkyl, -(CH2)q-S(O)2-cycloalkyl, -C(O)-lower alkyl, -(CH2)q-cycloalkyl, -C(O)CH2-O-lower alkyl, -(CH2)qCN, -C(O)CN, -C(O)CH2CN, lower alkyl substituted by halogen, lower alkenyl substituted by halogen, -C(O)-cycloalkyl wherein the cycloalkyl group is optionally substituted by cyano, lower alkyl, one or two halogen atoms, =0 or by amino, or is -C(O)O-lower alkyl or -(CH2)qO-lower alkyl and q is O - 3; or R6 and R7 may form together with the carbon atoms to which they are attach a five or six- membered non aromatic ring or R6 and R7 may form together with the nitrogen and carbon atoms to which they are attach a five or six-membered non aromatic ring; p is 0, 1 or 2; Ar is aryl- or heteroaryl, wherein the rings are optionally substituted by one or two substituents R"; R' ' is selected from hydrogen, halogen, lower alkyl, lower alkyl substituted by halogen, lower alkoxy, lower alkoxy substituted by halogen, -O-CH2-cycloalkyl, -NR4R5, -CN, -CH(CH3)CN, -CH2O-lower alkyl or pyrrolyl; m is 0, 1 or 2 and o is 0; o is 0, 1 or 2 and m is 1 or pharmaceutically active salts, racemic mixtures, enantiomers, optical isomers or tautomeric forms thereof. The compounds may be used for the treatment of depression, anxiety or schizophrenia.

    4-HYDROXY-4-METHYL-PIPERIDINE-1-CARBOXYLIC ACID(4-METHOXY-7-MORPHOLIN-4-YL-BENZOTHIAZOL-2-YL)-AMIDE

    公开(公告)号:MY140011A

    公开(公告)日:2009-11-30

    申请号:MYPI20052309

    申请日:2005-05-20

    Abstract: THE PRESENT INVENTION RELATES TO THE COMPOUND OF FORMULA 1 WHICH IS 4-HYDROXY-4-METHYL-PIPERIDINE- 1-CARBOXYLIC ACID (4-METHOXY-7-MORPHOLIN-4- YL-BENZOTHIAZOL-2-YL)AMIDE, AND PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALTS THEREOF, IT HAS BEEN FOUND THAT THE COMPOUND IS USEFUL FOR THE TREATMENT OR PREVENTION OF ALZHEIMER’S DISEASE, PARKINSON’S DISEASE, HUNTINGTON’S DISEASE, NEUROPROTECTION, SCHIZOPHRENIA, ANXIETY, PAIN, RESPIRATION DEFICITS, DEPRESSION, ADHD (ATTENTION DEFICIT HYPER-ACTIVITY DISORDER), DRUG ADDICTION TO AMPHETAMINES, COCAINE, OPIOIDS, ETHANOL, NICOTINE, CANNABINOIDS, OR FOR THE TREATMENT OF ASTHMA, ALLERGIC RESPONSES, HYPOXIA, ISCHEMIA, SEIZURE, SUBSTANCE ABUSE, OR FOR USE AS MUSCLE RELAXANTS, ANTIPSYCHOTICS, ANTIEPILEPTICS, ANTICONVULSANTS AND CARDIOPROTECTIVE AGENTS.

    PIRROLIDINA-ARIL-ETERES COMO ANTAGONISTAS DE RECEPTOR DE NK3

    公开(公告)号:PE20090898A1

    公开(公告)日:2009-07-13

    申请号:PE2008001308

    申请日:2008-08-05

    Abstract: REFERIDO A UN COMPUESTO DERIVADO DE PIRROLIDINA-ARIL-ETERES DE FORMULA (I): DONDE Ar1 Y Ar2 SON CADA UNO ARILO O HETEROARILO DE 5 O 6 ESLABONES; R1 ES H, HALOGENO, ALQUILO (C1-C8), ENTRE OTROS; R2 Y R4 SON CADA UNO HALOGENO, ALQUILO (C1-C8), ALQUILO (C1-C8) SUSTITUIDO POR HALOGENO O CIANO; R3 ES H, ALQUILO (C1-C8) O CH2OH; n, o Y p SON CADA UNO 1, 2 O 3; q ES 1 O 2. SON COMPUESTOS PREFERIDOS: 4-[(3SR-4RS)-3-[(RS)-1-(5-CLORO-PIRIDIN-2-ILOXI)-ETIL]-4-(3,4-DICLOROFENIL)-PIRROLIDINA-1-CARBONIL]-BENZONITRILO, 6-{(SR)-1-[(3RS,4SR)-4-(3,4-DICLORO-FENIL)-1-(4-OXAZOL-5-IL-BENZOIL)-PIRROLIDIN-3-IL]-ETOXI}-NICOTINONITRILO, 6-((SR)-1-{(3RS,4SR)-4-(3,4-DICLORO-FENIL)-1-[4-(3-METIL-[1,2,4]OXADIAZOL-5-IL)-BENZOIL]-PIRROLIDIN-3-IL}-ETOXI)-NICOTINONITRILO, ENTRE OTROS. TAMBIEN SE REFIERE A UNA FORMULACION Y A UN METODO DE PREPARACION. DICHO COMPUESTO ES ANTAGONISTA DEL RECEPTOR DE LA NK3 Y ES UTIL EN EL TRATAMIENTO DE LA DEPRESION, DOLOR, ENFERMEDAD DE PARKINSON Y TRASTORNOS RELACIONADOS

    PYRROLIDINE ARYL-ETHER AS NK3 RECEPTOR ANTAGONISTS

    公开(公告)号:CA2695211A1

    公开(公告)日:2009-02-12

    申请号:CA2695211

    申请日:2008-07-29

    Abstract: The invention relates to a compound of general formula (I) wherein Ar1 is aryl or a five or six membered heteroaryl; Ar2 is aryl or a five or six membered heteroaryl; R1 is hydrogen, halogen, lower alkyl, lower alkoxy, lower alkyl substituted by halogen, lower alkoxy substituted by halogen, S-lower alkyl, -S(O)2-lower alkyl, -S(O)2-di-lower alkyl amino, -(CH2)qR, cyano, amino, mono or di-lower alkyl amino, NHC(O)-lower alkyl, cycloalkyl or is or a five membered heteroaryl, optionally substituted by lower alkyl; wherein R is cyano, di-lower alkyl amino or pyrrolidin-1-yl; R2 is hydrogen, halogen, lower alkyl, lower alkyl substituted by halogen or cyano; R3 is hydrogen or lower alkyl or CH2OH; R4 is hydrogen, halogen, lower alkyl, lower alkyl substituted by halogen or cyano; n is 1, 2 or 3; in case n is 2 or 3, R1 may be the same or different; o is 1, 2 or 3; in case o is 2 or 3, R2 may be the same or different; p is 1, 2 or 3; in case p is 2 or 3, R4 may be the same or different; q is 1 or 2; or to a pharmaceutically active salt thereof, including all stereoisomeric forms, individual diastereoisomers and enantiomers of the compound of formula (I) as well as racemic and non-racemic mixtures thereof. It has been found that the present compounds are high potential NK-3 receptor antagonists for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD).

Patent Agency Ranking